0+ years
Nano-bio research
Founded 2016
Turn HOPE
into REALITY
Science into development, development into products—and products into changed lives.
Contact Us →
Science into development, development into products—and products into changed lives.
Contact Us →We engineer nano-carriers with precision so the drug reaches its target.
We turn candidate compounds into the optimal clinical-grade formulation.
We produce the finished formulation as reliable clinical trial material in our dedicated GMP facility.
BENCH to BEDSIDEBENCH to BEDSIDE
With proprietary nanotechnology we design the optimal formulation,With proprietary nanotechnology we design the optimal formulation,
so that what is possible in the lab becomesso that what is possible in the lab becomes
a medicine patients can actually receive.a medicine patients can actually receive.
From the depth of our research to the breadth of our commercialization—the results we can show.
Founded 2016
Korea, U.S., China, Australia and more
CEO record
In-house R&D center
Our flagship formulation development case.
We converted an oral drug into a topical and received IND approval. As of 2026 the Phase 1/2a trial is underway, with co-development agreements signed with four Korean pharmaceutical companies.
A lower dose than the oral drug, with comparable delivery efficiency
Blood drug concentration cut to this level, and side effects with it
H1 2027
From molecule to medicine — research, development and manufacturing in a single flow.
We select the delivery platform that best fits the candidate properties and the target tissue.
We developed oral dutasteride as a topical formulation, maintaining efficacy while reducing systemic exposure and side effects.*World-first topical dutasteride currently in clinical trials
We develop customized therapeutics by formulating candidate mRNA into LNPs tailored to its properties, enabling stable delivery to target organs in the body.
We formulate functional ingredients into LNPs for stable and efficient delivery deep into the skin.
We analyze how the formulation changes across temperatures and storage conditions, confirming under what conditions and for how long the clinical material holds its quality.
We produce clinical trial material in a GMP facility dedicated to nanoparticles, reducing the gap in technology transfer.
We take the lab formulation to production scale, optimizing process conditions so particle size and encapsulation efficiency hold steady as volume grows.